Clinical Scenario:
A 5-year-old boy receiving induction chemotherapy for precursor B-cell acute lymphoblastic leukemia develops persistent fever despite 4 days of appropriate broad-spectrum intravenous antibiotics. His absolute neutrophil count is 90/µL, blood cultures remain sterile, and no focus of bacterial infection is identified.
What is the most appropriate next step in management?
A. Add empirical antifungal therapy
B. Add vancomycin
C. Continue current antibiotics only
D. Stop all chemotherapy permanently
E. Start oral fluconazole
Correct answer & Explanation:
Correct Answer: A. Add empirical antifungal therapy
Explanation
This child has high-risk febrile neutropenia during induction chemotherapy for acute lymphoblastic leukemia. He has persistent fever despite receiving appropriate broad-spectrum intravenous antibiotics for 4 days, with profound neutropenia (ANC 90/µL) and negative blood cultures.
In children with prolonged neutropenia, persistent fever despite adequate antibacterial therapy raises strong suspicion for an invasive fungal infection, even when no organism has been isolated. Blood cultures are frequently negative in invasive fungal disease; therefore, treatment should not be delayed while awaiting microbiological confirmation.
According to Nelson Textbook of Pediatrics, IDSA, and ECIL guidelines, empirical systemic antifungal therapy should be initiated in high-risk neutropenic patients whose fever persists for 72–96 hours despite appropriate antibacterial therapy.
Why the other options are incorrect
A. Add empirical antifungal therapy
Correct. Persistent fever after 4 days of appropriate antibiotics in a child with profound neutropenia warrants empirical antifungal therapy.
B. Add vancomycin
Vancomycin is not routinely added for persistent fever alone. It is reserved for specific indications such as suspected catheter-related infection, skin or soft tissue infection, hemodynamic instability, severe mucositis, or documented resistant Gram-positive infection.
C. Continue current antibiotics only
Continuing antibiotics alone may delay treatment of invasive fungal infection, which is associated with significant morbidity and mortality.
D. Stop all chemotherapy permanently
Chemotherapy may be temporarily withheld depending on the patient’s clinical status, but permanent discontinuation is not indicated because of febrile neutropenia.
E. Start oral fluconazole
Oral fluconazole is not appropriate as empirical therapy in this setting because it lacks activity against many filamentous fungi, particularly Aspergillus species, which are important pathogens in prolonged neutropenia.
Learning Point
Persistent fever for ≥72–96 hours in a child with high-risk febrile neutropenia despite appropriate broad-spectrum antibacterial therapy should prompt empirical systemic antifungal therapy, even if blood cultures remain negative. Early treatment reduces the risk of invasive fungal disease and improves outcomes.
